ReviewClinical liver disease2015
New treatments for HCV: Perspective from Asia.
Review in Clinical liver disease, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing.Hepatology international · 2016Guideline
- Trial
- Machine learning-based prediction of treatment response in comorbid hepatitis C patients receiving DAA therapy: a real-world study from Pakistan.Frontiers in public health · 2026Article
- Post-Treatment Occurrence of Serum Cryoglobulinemia in Chronic Hepatitis C Patients.Diagnostics (Basel, Switzerland) · 2024Article
- Towards a safe hospital: hepatitis C in-hospital micro-elimination program (HCV-HELP study).Hepatology international · 2022Article
- Persistent cryoglobulinemia after antiviral treatment is associated with advanced fibrosis in chronic hepatitis C patients.PloS one · 2022Article
- Challenges to Differentiate Hepatitis C Genotype 1 and 6: Results from A Field-Study in Cambodia.Infectious diseases and therapy · 2020Article
- Article
- Systematic review and meta-analysis: real-world effectiveness of direct-acting antiviral therapies in chronic hepatitis C genotype 3 in Asia.BMJ open gastroenterology · 2018Article
- Hepatitis C virus therapy with peg-interferon and ribavirin in Myanmar: A resource-constrained country.World journal of gastroenterology · 2016Observational
- Article
- APASL consensus statements and recommendation on treatment of hepatitis C.Hepatology international · 2016Review
- Peginterferon plus Ribavirin for HIV-infected Patients with Treatment-Naïve Acute or Chronic HCV Infection in Taiwan: A Prospective Cohort Study.Scientific reports · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.